市場調查報告書
商品編碼
1390572
2023-2028 年按設備技術、應用、最終用戶和地區分類的消融設備市場報告Ablation Devices Market Report by Device Technology, Application, End User, and Region 2023-2028 |
2022年全球消融器械市場規模達52億美元。展望未來, IMARC Group預計到2028年市場規模將達到102億美元,2022-2028年複合年成長率(CAGR)為11.88%。危及生命的疾病的日益流行、電生理學去除異常組織的廣泛採用,以及帶有機器人導航系統的下一代消融設備的開發,是推動市場發展的一些關鍵因素。
消融裝置是在各種醫療程序中用於移除或破壞組織的醫療器械或工具,通常目的是治療或控制某些醫療狀況。這些設備的工作原理是將熱、冷或射頻等能量傳遞到目標組織,導致其被去除或改變。消融手術是微創手術,通常比傳統手術方法更受青睞,因為它們通常可以減輕疼痛、縮短恢復時間並降低併發症的風險。
該市場正在經歷由幾個關鍵因素推動的成長,包括癌症、心房顫動和慢性靜脈功能不全(CVI)等危及生命的疾病的盛行率不斷上升。疾病發生率的上升凸顯了對有效消融手術的需求。此外,大眾對微創消融技術可用性的認知不斷增強,正在推動市場擴張。這些手術具有許多優點,包括減輕疼痛、最小化疤痕、減少不適以及加速患者康復時間。此外,廣泛採用電生理學程序透過移除異常組織來解決心律不整和心律不整,這對市場成長做出了重大貢獻。此外,製造商還透過開發專為有效治療淺靜脈逆流而設計的非熱、非腫脹和非硬化靜脈內消融裝置來應對不斷變化的醫療需求。
危及生命的疾病的盛行率不斷增加
癌症仍然是全世界死亡的主要原因之一,近年來發病率不斷上升。消融手術,特別是在腫瘤學領域,作為手術的微創替代方案而受到重視。它們被用來破壞各種器官中的癌組織,例如肝臟、腎臟和肺臟。此外,CVI 是一種腿部靜脈無法將血液充分返回心臟的疾病,導致疼痛、腫脹和皮膚變化。靜脈內消融手術現在通常用於透過封閉故障靜脈來治療 CVI。 CVI 發病率的上升通常與生活方式因素和衰老有關,這推動了對用於靜脈治療的消融設備的需求。
電生理學的廣泛採用
電生理學是心臟病學的一個分支,研究心臟的電活動。由於其在診斷和治療包括心房顫動在內的各種心律不整方面的有效性,它的採用率激增。電生理學引導的消融手術涉及精確定位和消除心臟中異常電訊號的來源。這種方法已成為許多心律不整的護理標準,為患者提供緩解症狀和提高生活品質的機會。此外,隨著醫療保健專業人員越來越認知到電生理引導消融的好處,其採用已經廣泛,導致對相關消融裝置和設備的需求不斷成長。
下一代消融設備與機器人導航系統的整合
消融設備領域的技術進步是一個重要的驅動力。下一代消融設備採用機器人導航系統,可提高精準度、準確度和手術結果。機器人輔助消融可以實現更受控和更有針對性的組織消融,降低併發症的風險並改善患者的治療效果。這些機器人系統提供治療區域的即時成像和繪圖,使醫療保健提供者能夠更有信心地導航複雜的解剖結構。因此,這些先進消融設備的採用正在增加,特別是在尋求提供最先進治療選擇的醫療機構中。提高病人安全性和手術成功率的承諾進一步刺激了對這些設備的需求。
IMARC Group提供了全球消融設備市場報告各細分市場主要趨勢的分析,以及 2023 年至 2028 年全球、區域和國家層面的預測。我們的報告根據設備技術、應用和最終用戶對市場進行了分類。
射頻設備
雷射/光燒蝕
超音波設備
冷凍消融設備
其他
射頻設備代表最常用的設備技術
該報告根據設備技術對市場進行了詳細的細分和分析。這包括射頻設備、雷射/光消融、超音波設備、冷凍消融設備等。根據該報告,射頻設備佔據了最大的佔有率。
射頻消融術已在廣泛的醫療應用中證明了有效性。它用於治療心律不整(例如心房顫動)、肝臟腫瘤、腎臟腫瘤和慢性疼痛管理等疾病。這種多功能性使射頻技術成為處理各種醫學專業的醫生的首選。此外,射頻消融在醫療手術中有著安全、成功使用的悠久歷史。該技術多年來不斷完善,臨床醫生在其應用方面擁有豐富的經驗。這種安全性和有效性的記錄為醫療保健提供者和患者註入了信心。
癌症治療
心血管疾病治療
眼科治療
婦科治療
泌尿科治療
整容手術
其他
癌症治療佔據最大市場佔有率
報告還提供了基於應用程式的詳細市場細分和分析。這包括癌症治療、心血管疾病治療、眼科治療、婦科治療、泌尿科治療、整形手術等。報告稱,癌症治療佔最大部分。
癌症是一種廣泛流行的疾病,影響全球數百萬人。它可以發生在各種器官和組織中,導致對有效治療方案的高需求。由於人口老化和生活方式改變等因素,癌症發生率持續上升,對包括消融在內的癌症治療方法的需求仍然很大。此外,消融技術已被證明在腫瘤學領域具有多種用途。這些手術可用於治療原發性腫瘤和轉移性病變,使其適用於不同階段和類型的癌症。消融可用於多種器官,如肝臟、腎臟、肺臟和骨骼,為臨床醫生提供了廣泛的治療選擇。
醫院
門診手術中心
其他
醫院佔大部分市場佔有率
報告還提供了基於最終用戶的詳細市場細分和分析。這包括半導體和電子、汽車、航空航太和國防、醫療等。報告稱,醫院佔最大部分。
消融手術通常需要專門的設備和訓練有素的醫療專業人員。醫院設備齊全,可以處理複雜的醫療干預措施,並擁有必要的基礎設施,包括手術室、影像技術和支援人員,以安全有效地執行這些程序。這使得醫院成為尋求消融治療的患者的自然選擇。此外,醫院還擁有廣泛的醫學專科,包括心臟科、腫瘤學、胃腸病學、泌尿科等。消融設備用於多個醫學學科來治療各種病症。醫院可以提供全面的消融服務,使其成為具有不同醫療需求的患者的一站式目的地。
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
北美在市場上表現出明顯的主導地位
市場研究報告還對所有主要區域市場進行了全面分析,其中包括北美(美國和加拿大);歐洲(德國、法國、英國、義大利、西班牙、俄羅斯等);亞太地區(中國、日本、印度、韓國、澳洲、印尼等);拉丁美洲(巴西、墨西哥等);以及中東和非洲。報告稱,北美佔據最大的市場佔有率。
北美,特別是美國和加拿大,擁有高度發展和先進的醫療基礎設施。該地區擁有世界知名的醫療機構、醫院和研究中心。這種先進的基礎設施為採用尖端醫療技術(包括消融設備)提供了堅實的基礎。此外,該地區是世界上醫療保健支出最高的地區之一。政府和私人實體對醫療保健的大量投資使得能夠採購最先進的醫療設備,包括消融設備。它還支持醫療保健領域的研究和開發工作,從而促進創新和產品進步。
市場競爭格局的特點是存在多個參與者,包括知名品牌、新興新創公司和專業製造商。目前,領先的公司正在投入大量資源進行研發工作,以開發創新且技術先進的消融設備。這包括開發具有更高精度、安全功能和方便用戶使用介面的下一代消融系統。他們還擴大產品組合,提供全面的消融設備,以滿足各種醫療專業和應用的需求。這包括設計用於心臟消融、腫瘤學、疼痛管理、婦科等的設備。此外,公司正在將業務範圍擴大到新的地域市場。這種擴張涉及獲得不同地區的監管批准和認證、建立分銷網路以及調整其產品以滿足特定地區的要求。
雅培實驗室
血管動力學公司
阿特里庫爾公司
波士頓科學公司
康邁德公司
Elekta AB(出版)
強生公司
美敦力公司
奧林巴斯公司
全錄輝公司
(請注意,這只是關鍵參與者的部分列表,報告中提供了完整列表。)
雅培在消融設備領域取得了顯著的發展。他們推出了 EnSite Precision (TM) 心臟測繪系統,該系統可提供高解析度成像和準確的心臟測繪。此技術能夠在消融過程中精確識別異常組織,提高治療的成功率。
強生公司一直積極參與創新消融技術的開發。該公司推出了 TactiCath 接觸力消融導管,可提供心臟消融手術期間施加的力量的即時回饋。這有助於實現更好的結果並降低併發症的風險。
美敦力公司推出了 Arctic Front Advance Cryoballoon 系統,用於治療心房顫動。該系統提高了心臟消融手術的效率和精確度。
The global ablation devices market size reached US$ 5.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2028, exhibiting a growth rate (CAGR) of 11.88% during 2022-2028. The increasing prevalence of life-threatening diseases, the widespread adoption of electrophysiology to remove abnormal tissues, and the development of next-generation ablation devices with robotic navigation systems represent some of the key factors driving the market.
Ablation devices are medical instruments or tools used in various medical procedures to remove or destroy tissue, typically with the goal of treating or managing certain medical conditions. These devices work by delivering energy, such as heat, cold, or radiofrequency, to the targeted tissue, causing its removal or alteration. Ablation procedures are minimally invasive and are often preferred over traditional surgical methods because they typically result in less pain, shorter recovery times, and reduced risk of complications.
The market is experiencing growth driven by several key factors, including the increasing prevalence of life-threatening diseases such as cancer, atrial fibrillation, and chronic venous insufficiency (CVI). This rise in disease incidence underscores the demand for effective ablation procedures. Furthermore, the growing awareness among the public about the availability of minimally invasive ablation techniques is propelling market expansion. These procedures offer numerous advantages, including reduced pain, minimal scarring, decreased discomfort, and quicker patient recovery times. Additionally, the widespread adoption of electrophysiology procedures to address irregular heart rhythms and cardiac arrhythmia by removing abnormal tissues is contributing significantly to market growth. Besides, manufacturers are also responding to evolving medical needs by creating non-thermal, non-tumescent, and non-sclerosant endovenous ablation devices tailored for the effective treatment of superficial vein reflux.
Increasing prevalence of life-threatening diseases
Cancer remains one of the leading causes of death worldwide, with a rising incidence in recent years. Ablation procedures, particularly in oncology, have gained prominence as minimally invasive alternatives to surgery. They are employed to destroy cancerous tissues in various organs, such as the liver, kidney, and lung. Moreover, CVI is a condition where veins in the legs fail to adequately return blood to the heart, leading to pain, swelling, and skin changes. Endovenous ablation procedures are now commonly used to treat CVI by closing off malfunctioning veins. The rising incidence of CVI, often associated with lifestyle factors and aging, has driven the demand for ablation devices designed for venous treatments.
Widespread adoption of electrophysiology
Electrophysiology is a branch of cardiology that deals with the electrical activity of the heart. It has witnessed a surge in adoption due to its effectiveness in diagnosing and treating various cardiac arrhythmias, including atrial fibrillation. Electrophysiology-guided ablation procedures involve precisely locating and eliminating the source of abnormal electrical signals in the heart. This approach has become the standard of care for many heart rhythm disorders, offering patients a chance for symptom relief and improved quality of life. Moreover, with healthcare professionals increasingly recognizing the benefits of electrophysiology-guided ablation, its adoption has become widespread, leading to a growing demand for related ablation devices and equipment.
Integration of next-generation ablation devices with robotic navigation systems
The advancement of technology in the field of ablation devices is a significant driving force. Next-generation ablation devices incorporate robotic navigation systems, which enhance precision, accuracy, and procedural outcomes. Robotic-assisted ablation allows for more controlled and targeted tissue ablation, reducing the risk of complications and improving patient outcomes. These robotic systems provide real-time imaging and mapping of the treatment area, enabling healthcare providers to navigate complex anatomical structures with greater confidence. As a result, the adoption of these advanced ablation devices is on the rise, particularly among healthcare facilities looking to offer state-of-the-art treatment options. The promise of improved patient safety and procedural success rates further fuels the demand for these devices.
IMARC Group provides an analysis of the key trends in each segment of the global ablation devices market report, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on device technology, application and end user.
Radiofrequency Devices
Laser/Light Ablation
Ultrasound Devices
Cryoablation Devices
Others
Radiofrequency devices represent the most used device technology
The report has provided a detailed breakup and analysis of the market based on the device technology. This includes radiofrequency devices, laser/light ablation, ultrasound devices, cryoablation devices, and others. According to the report, radiofrequency devices represented the largest segment.
RF ablation has demonstrated effectiveness across a wide range of medical applications. It is used to treat conditions such as cardiac arrhythmias (e.g., atrial fibrillation), liver tumors, kidney tumors, and chronic pain management. This versatility makes RF technology a go-to choice for physicians dealing with various medical specialties. Moreover, RF ablation has a long history of safe and successful use in medical procedures. The technology has been refined over the years, and clinicians have extensive experience with its application. This track record of safety and efficacy instills confidence in both healthcare providers and patients.
Cancer Treatment
Cardiovascular Disease Treatment
Ophthalmologic Treatment
Gynecological Treatment
Urological Treatment
Cosmetic Surgery
Others
Cancer treatment holds the largest market share
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes cancer treatment, cardiovascular disease treatment, ophthalmologic treatment, gynecological treatment, urological treatment, cosmetic surgery, and others. According to the report, cancer treatment represented the largest segment.
Cancer is a widespread and prevalent disease that affects millions of people globally. It can occur in various organs and tissues, leading to a high demand for effective treatment options. As the incidence of cancer continues to rise due to factors like aging populations and lifestyle changes, the need for cancer treatment methods, including ablation, remains significant. Moreover, ablation techniques have proven to be versatile in the field of oncology. These procedures can be used to treat both primary tumors and metastatic lesions, making them applicable across different stages and types of cancer. Ablation can be employed in various organs, such as the liver, kidney, lung, and bone, providing clinicians with a wide range of treatment options.
Hospitals
Ambulatory Surgical Centers
Others
Hospitals accounts for majority of market share
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes semiconductor and electronics, automotive, aerospace and defense, medical, and others. According to the report, hospitals represented the largest segment.
Ablation procedures often require specialized equipment and trained medical professionals. Hospitals are well-equipped to handle complex medical interventions and have the necessary infrastructure, including operating rooms, imaging technology, and support staff, to perform these procedures safely and effectively. This makes hospitals the natural choice for patients seeking ablation treatments. Moreover, hospitals house a wide range of medical specialties, including cardiology, oncology, gastroenterology, urology, and more. Ablation devices are used across multiple medical disciplines to treat various conditions. Hospitals can offer a comprehensive suite of ablation services, making them a one-stop destination for patients with diverse medical needs.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America, particularly the United States and Canada, boasts a highly developed and advanced healthcare infrastructure. The region is home to world-renowned medical institutions, hospitals, and research centers. This advanced infrastructure provides a solid foundation for the adoption of cutting-edge medical technologies, including ablation devices. Moreover, the region has one of the highest healthcare expenditure rates in the world. This substantial investment in healthcare, both by governments and private entities, enables the procurement of state-of-the-art medical equipment, including ablation devices. It also supports research and development efforts in the healthcare sector, leading to innovation and product advancements.
The competitive landscape of the market is characterized by the presence of multiple players that include established brands, emerging startups, and specialty manufacturers. Presently, leading companies are allocating significant resources to research and development efforts to develop innovative and technologically advanced ablation devices. This includes the development of next-generation ablation systems with enhanced precision, safety features, and user-friendly interfaces. They are also expanding their product portfolios to offer a comprehensive range of ablation devices catering to various medical specialties and applications. This includes devices designed for cardiac ablation, oncology, pain management, gynecology, and more. Moreover, companies are expanding their reach into new geographical markets. This expansion involves obtaining regulatory approvals and certifications in different regions, establishing distribution networks, and adapting their products to meet specific regional requirements.
Abbott Laboratories
AngioDynamics Inc.
AtriCure Inc.
Boston Scientific Corporation
CONMED Corporation
Elekta AB (publ)
Johnson & Johnson
Medtronic plc
Olympus Corporation
Smith & Nephew plc
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
Abbott has made notable developments in the field of ablation devices. They have introduced the EnSite Precision™ cardiac mapping system, which offers high-resolution imaging and accurate mapping of the heart. This technology enables precise identification of abnormal tissue during ablation procedures, improving the success rate of the treatment.
Johnson & Johnson has been actively involved in the development of innovative ablation technologies. It has introduced the TactiCath Contact Force Ablation Catheter, which provides real-time feedback on the amount of force applied during cardiac ablation procedures. This helps in achieving better outcomes and reducing the risk of complications.
Medtronic Plc have introduced the Arctic Front Advance Cryoballoon System, which is used for the treatment of atrial fibrillation. This system offers improved efficiency and precision in cardiac ablation procedures.